We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

274 hedge funds and large institutions have $3.85B invested in Intra-Cellular Therapies Inc. in 2022 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 103 increasing their positions, 86 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 35

20% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 86

13% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $18.9M

3% more funds holding

Funds holding: 266 → 274 (+8)

16% less capital invested

Capital invested by funds: $4.57B → $3.85B (-$727M)

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
274
Holders Change
+8
Holders Change %
+3.01%
% of All Funds
4.72%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
43
Increased
103
Reduced
86
Closed
35
Calls
$21.3M
Puts
$18.9M
Net Calls
+$2.43M
Net Calls Change
-$6.17M

Top Buyers

1
GKIM
GW&K Investment Management
Massachusetts
+$46.1M
2
Invesco
Invesco
Georgia
+$45.3M
3
Millennium Management
Millennium Management
New York
+$42M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$36.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$34.3M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$43.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$36.5M
3
DCM
Driehaus Capital Management
Illinois
-$29.4M
4
SCM
Suvretta Capital Management
New York
-$25.4M
5
CAM
Cormorant Asset Management
Massachusetts
-$15.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
EGI
276
EAM Global Investors
California
– -$2.16M -37,763 Closed
AR
277
Advisory Research
Illinois
– -$2.08M -36,414 Closed
EI
278
EAM Investors
California
– -$1.88M -32,849 Closed
HM
279
HealthCor Management
New York
– -$1.54M -27,070 Closed
DTL
280
Dynamic Technology Lab
Singapore
– -$1.02M -17,910 Closed
JCIA
281
Jackson Creek Investment Advisors
Colorado
– -$928K -17,143 Closed
NIM
282
NXG Investment Management
Texas
– -$756K -13,248 Closed
Allianz Asset Management
283
Allianz Asset Management
Germany
– -$711K -12,450 Closed
HMS
284
Hanseatic Management Services
New Mexico
– -$583K -10,219 Closed
Arrowstreet Capital
285
Arrowstreet Capital
Massachusetts
– -$527K -9,238 Closed
TI
286
Trexquant Investment
Connecticut
– -$477K -8,360 Closed
CAM
287
ClariVest Asset Management
California
– -$436K -7,633 Closed
SCA
288
Spearhead Capital Advisors
Florida
– -$365K -6,401 Closed
SEC
289
Seven Eight Capital
New York
– -$355K -6,219 Closed
OQS
290
Occudo Quantitative Strategies
Florida
– -$343K -6,008 Closed
MF
291
Magnetar Financial
Illinois
– -$298 -5,223 Closed
SLT
292
St Louis Trust
Missouri
– -$285K -5,000 Closed
AG
293
Algert Global
California
– -$246K -4,301 Closed
OSAM
294
O'Shaughnessy Asset Management
Connecticut
– -$233K -4,084 Closed
PM
295
Parametrica Management
Hong Kong
– -$231K -4,072 Closed
PM
296
Penbrook Management
New York
– -$228K -4,000 Closed
Janney Montgomery Scott
297
Janney Montgomery Scott
Pennsylvania
– -$203K -3,668 Closed
YIH
298
Y-Intercept (HK)
Hong Kong
– -$205K -3,593 Closed
PFS
299
Prospera Financial Services
Texas
– -$66K -1,152 Closed
CAPTRUST Financial Advisors
300
CAPTRUST Financial Advisors
North Carolina
– -$56K -984 Closed
9 10 11
12
13

ITCI Hedge Fund Activity: Q3 2022 in Review

274 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2022, worth a combined $3.85B — down 16% from $4.57B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new ITCI positions and 35 closed out — a net gain of 8 holders — while 103 added to existing stakes and 86 trimmed.

The largest buyer was GW&K Investment Management, adding an estimated $46.1M. The largest seller was Victory Capital Management, cutting an estimated $43.9M.

  • 274 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2022, up from 266 in Q2 2022.
  • Funds reported $3.85B of Intra-Cellular Therapies Inc. stock for Q3 2022, down 16% quarter-over-quarter.
  • 43 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2022 and 35 closed out, a net change of +8 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2022 was GW&K Investment Management, an estimated $46.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2022 was Victory Capital Management, an estimated $43.9M sold.

Based on aggregated 13F filings for Q3 2022.